| 0.0005 0 (25%) | 12-12 15:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0 | 1-year : | 0 |
| Resists | First : | 0 | Second : | 0 |
| Pivot price | 0 | |||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 | MA(20) : | 0  |
| MA(100) : | 0 |
MA(250) : | 0.02  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.1 | D(3) : | 10.1 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 0.1 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EVLO ] has closed above bottom band by 48.8%. Bollinger Bands are 82.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Wed, 22 Nov 2023
Flagship-Founded Microbiome Company Evelo Biosciences Throws in the Towel - BioSpace
Wed, 22 Nov 2023
Flagship-backed microbiome biotech Evelo to shut down - BioPharma Dive
Tue, 17 Oct 2023
Evelo Biosciences Inc. Halted, News Pending - Investing.com
Tue, 17 Oct 2023
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis - StockTitan
Thu, 27 Apr 2023
Why Is Baudax Bio (BXRX) Stock Down 52% Today? - InvestorPlace
Sun, 16 May 2021
Evelo Biosciences: Monoclonal Microbes Offer Novel Inflammatory Treatment With A Favorable Risk-Reward Profile - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 197 (K) |
| Shares Short P.Month | 156 (K) |
| EPS | -15.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|